A new mouse model resembling human diabetic nephropathy: Uncoupling of VEGF with eNOS as a novel pathogenic mechanism

Clinical Nephrology

Volumn 71, Issue 2, 2009, Pages 103-109

  Nakagawa, Takahiko ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Endothelial dysfunction; Kimmelstiel; Mesangiolysis; Microaneurysm; Nitric oxide; Uncoupling; VEGF; Wilson

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN A;

ANTIINFLAMMATORY ACTIVITY; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; DIABETIC NEPHROPATHY; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; HUMAN; MACROPHAGE; NEOVASCULARIZATION (PATHOLOGY); OXIDATIVE PHOSPHORYLATION UNCOUPLING; PATHOPHYSIOLOGY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; ANIMAL; DISEASE MODEL; METABOLISM; MOUSE;

ANIMALS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; MICE; NITRIC OXIDE SYNTHASE TYPE III; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 64549148523     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71103     Document Type: Review

References (36)

1. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996; 87: 3336-3343.
2. Chan WB, Chan NN, Lai CW, So WY, Lo MK, Lee KF, Chow CC, Metreweli C, Chan JC. Vascular defect beyond the endothelium in type II diabetic patients with overt nephropathy and moderate renal insufficiency. Kidney Int. 2006; 70: 711-716.
3. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003; 111: 707-716.
4. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008; 358: 1129-1136.
5. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes. 2002; 51: 3090-3094.
6. Galkina E, Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol. 2006; 17: 368-377.
7. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998; 21: 518-524.
8. Heeringa P, van Goor H, Itoh-Lindstrom Y, Maeda N, Falk RJ, Assmann KJ, Kallenberg CG, Jennette JC. Lack of endothelial nitric oxide synthase aggravates murine accelerated anti-glomerular basement membrane glomerulonephritis. Am J Pathol. 2000; 156: 879-888.
9. Ichinose K, Maeshima Y, Yamamoto Y, Kitayama H, Takazawa Y, Hirokoshi K, Sugiyama H, Yamasaki Y, Eguchi K, Makino H. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes. 2005; 54: 2891-2903.
10. Iruela-Arispe L, Gordon K, Hugo C, Duijvestijn AM, Claffey KP, Reilly M, Couser WG, Alpers CE, Johnson RJ. Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol. 1995; 147: 1715-1727.
11. Jawa A, Nachimuthu S, Pendergrass M, Asnani S, Fonseca V. Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy. J Clin Endocrinol Metab. 2006; 91: 31-35.
12. Johnson RJ, Segal MS, Srinivas T, Ejaz A, Mu W, Roncal C, Sanchez-Lozada LG, Gersch M, Rodriguez-Iturbe B, Kang DH, Acosta JH. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol. 2005; 16: 1909-1919.
13. Kanesaki Y, Suzuki D, Uehara G, Toyoda M, Katoh T, Sakai H, Watanabe T. Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis. 2005; 45: 288-294.
14. Kanetsuna Y, Takahashi K, Nagata M, Gannon MA, Breyer MD, Harris RC, Takahashi T. Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. Am J Pathol. 2007; 170: 1473-1484.
15. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol. 2001a; 12: 1434-1447.
16. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol. 2001b; 12: 1448-1457.
17. Kang DH, Nakagawa T, Feng L, Johnson RJ. Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol. 2002; 161: 239-248.
18. Lefer DJ, Jones SP, Girod WG, Baines A, Grisham MB, Cockrell AS, Huang PL, Scalia R. Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. Am J Physiol. 1999; 276: H1943-1950.
19. Nakagawa T. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol. 2007; 292: F1665-1672.
20. Nakagawa T, Sato W, Sautin YY, Glushakova O, Croker B, Atkinson MA, Tisher CC, Johnson RJ. Uncoupling of vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy. J Am Soc Nephrol. 2006; 17: 736-745.
21. Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, Yuzawa Y, Atkinson M, Johnson RJ, Croker B. Diabetic eNOS knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol. 2007; 18: 539-550.
22. Nyengaard JR, Rasch R. The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia. 1993; 36: 189-194.
23. Osterby R, Nyberg G. New vessel formation in the renal corpuscles in advanced diabetic glomerulopathy. J Diabet Complications. 1987; 1: 122-127.
24. Osterby R, Asplund J, Bangstad HJ, Nyberg G, Rudberg S, Viberti GC, Walker JD. Neovascularization at the vascular pole region in diabetic glomerulopathy. Nephrol Dial Transplant. 1999; 14: 348-352.
25. Papaioannou GI, Seip RL, Grey NJ, Katten D, Taylor A, Inzucchi SE, Young LH, Chyun DA, Davey JA, Wackers FJ, Iskandrian AE, Ratner RE, Robinson EC, Carolan S, Engel S, Heller GV. Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study). Am J Cardiol. 2004; 94: 294-299.
26. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis. 1999; 34: 795-808.
27. Sakamoto T, Ishibashi T, Sakamoto N, Sugimoto K, Egashira K, Ohkawara H, Nagata K, Yokoyama K, Kamioka M, Ichiki T, Sugimoto N, Kurabayashi M, Suzuki K, Takuwa Y, Maruyama Y. Endogenous NO blockade enhances tissue factor expression via increased Ca2+ influx through MCP-1 in endothelial cells by monocyte adhesion. Arterioscler Thromb Vasc Biol. 2005; 25: 2005-2011.
28. Sato W, Zhang LN, Roncal C, Heinig M, Campbell-Thompson M, Atkinson M, Croker B, Nakagawa T. The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy. Lab Invest. 2008; 88: 949-961.
29. Schrijvers BF, Flyvbjerg A, de Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004; 65: 2003-2017.
30. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol. 2001; 12: 993-1000.
31. Yamamoto Y, Maeshima Y, Kitayama H, Kitamura S, Takazawa Y, Sugiyama H, Yamasaki Y, Makino H. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes. 2004; 53: 1831-1840.
32. Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant. 2008; 23: 1621-1627.
33. Zhang LN, Wilson DW, da Cunha V, Sullivan ME, Vergona R, Rutledge JC, Wang YX. Endothelial NO synthase deficiency promotes smooth muscle progenitor cells in association with upregulation of stromal cell-derived factor-1{alpha} in a mouse model of carotid artery ligation. Arterioscler Thromb Vasc Biol. 2006; 36: 765-772.
34. Zhang SX, Wang JJ, Lu K, Mott R, Longeras R, Ma JX. Therapeutic potential of angiostatin in diabetic nephropathy. J Am Soc Nephrol. 2006; 17: 475-486.
35. Zhao Q, Egashira K, Inoue S, Usui M, Kitamoto S, Ni W, Ishibashi M, Hiasa Ki K, Ichiki T, Shibuya M, Takeshita A. Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation. 2002; 105: 1110-1115.
36. Zhao HJ, Wang S, Cheng H, Zhang MZ, Takahashi T, Fogo AB, Breyer MD, Harris RC. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol. 2006; 17: 2664-2669.